University of South Florida

Scholar Commons
Graduate Theses and Dissertations

Graduate School

2006

Crystal engineering of novel pharmaceutical forms
Jennifer Anne McMahon
University of South Florida

Follow this and additional works at: http://scholarcommons.usf.edu/etd
Part of the American Studies Commons
Scholar Commons Citation
McMahon, Jennifer Anne, "Crystal engineering of novel pharmaceutical forms" (2006). Graduate Theses and Dissertations.
http://scholarcommons.usf.edu/etd/2625

This Thesis is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate
Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact scholarcommons@usf.edu.

Crystal Engineering of Novel Pharmaceutical Forms

by

Jennifer Anne McMahon

A thesis submitted in partial fulfillment
of the requirements for the degree of
Master of Science
Department of Chemistry
College of Arts and Sciences
University of South Florida

Major Professor: Michael J. Zaworotko, Ph.D.
Randy Larsen, Ph.D.
Mohamed Eddaoudi, Ph.D.
Date of Approval:
November 7, 2006

Keywords: hydrogen bonding, co-crystal, primary amide, polymorphism, heterosynthon
© Copyright 2006, Jennifer A. McMahon

Acknowledgements
For all the support and help, I would like to thank:
Dr. Michael J. Zaworotko
TransForm Pharmaceuticals, Inc.
Joanna Bis
Tanise Shattock
Leslie Morales
Scott Fleischmann
Peddy Vishweshwar

Table of Contents
List of Tables

iv

List of Figures

v

Abstract

vii

Chapter 1- Introduction
1.1 Crystal Engineering
1.2 Supramolecular Synthons
1.3 Co-crystals
1.4 Pharmaceutical Co-crystals
1.5 Polymorphism
1.6 Cambridge Structural Database

1
1
3
5
7
9
9

Chapter 2- Polymorphism in Single Component Systems
2.1 Introduction
2.2 BHA
2.2.1 Description (A, B)
2.2.2 Synthesis and Characterization
2.2.3 Discussion
2.3 Aspirin
2.3.1 Description (C, D)
2.3.2 Synthesis and Characterization
2.4 Discussion

11
11
12
12
13
14
15
15
19
21

Chapter 3- CSD analysis of Primary Amides
3.1 Primary Amide Homosynthons
3.2 Primary Amide Heterosynthons
3.3 Discussion

22
22
24
27

Chapter 4- Model Compounds
4.1 Description
4.2 Strategy
4.3 Structures
4.3.1 nicotinamide/3-hydroxybenzoic acid (A)
4.3.2 nicotinamide/4-hydroxybenzoic acid (B)
4.3.3 nicotinamide/gentisic acid (C)

29
29
30
30
30
31
32

i

4.3.4 pyrazinamide/gentisic acid (D)
4.3.5 acetamide/ gentisic acid (E)
4.4 Synthesis and Characterization
4.4.1 nicotinamide/3-hydroxybenzoic acid (A)
4.4.2 nicotinamide/4-hydroxybenzoic acid (B)
4.4.3 nicotinamide/gentisic acid (C)
4.4.4 pyrazinamide/gentisic acid (D)
4.4.5 acetamide/gentisic acid (E)
4.5 Discussion

33
33
34
34
35
35
36
36
37

Chapter 5- Piracetam
5.1 Description
5.2 Strategy
5.3 Structures
5.3.1 Piracetam/gentisic acid (A)
5.3.2 Piracetam/4-hydroxybenzoic acid (B)
5.4 Synthesis and Characterization
5.4.1 Piracetam/gentisic acid (A)
5.4.2 Piracetam/4-hydroxybenzoic acid (B)
5.5 Discussion

39
39
40
40
40
41
43
43
43
44

Chapter 6- Carbamazepine
6.1 Description
6.2 Strategy 1
6.3 Structures
6.3.1 CBZ/benzoquinone (A)
6.3.2 CBZ/4,4’-bipyridine (B)
6.3.3 CBZ/cinnamic acid (C)
6.3.4 CBZ/formamide solvate (D)
6.4 Synthesis and Characterization
6.4.1 CBZ/benzoquinone (A)
6.4.2 CBZ/4,4’-bipyridine (B)
6.4.3 CBZ/cinnamic acid (C)
6.4.4 CBZ/formamide solvate (D)
6.5 Strategy 2
6.6 Structures
6.6.1 CBZ/acetylsalicylic acid (E)
6.6.2 CBZ/4-aminobenzoic acid (F)
6.6.3 CBZ/4-aminobenzoic acid hydrate (G)
6.6.4 CBZ/trimesic acid (H)
6.6.5 CBZ/5-nitroisophthalic acid (I)
6.6.6 CBZ/2,6-pyridinedicarboxylic acid (J)
6.6.7 CBZ/acetic acid solvate (K)
6.6.8 CBZ/formic acid solvate (L)

46
46
48
49
49
50
50
51
52
52
52
53
53
54
54
54
55
56
57
58
58
60
60

ii

6.6.9 CBZ/butyric acid solvate (M)
6.6.10 CBZ/benzenesulfonate (N)
6.7 Synthesis and Characterization
6.7.1 CBZ/acetylsalicylic acid (E)
6.7.2 CBZ/4-aminobenzoic acid (F)
6.7.3 CBZ/4-aminobenzoic acid hydrate (G)
6.7.4 CBZ/trimesic acid (H)
6.7.5 CBZ/5-nitroisophthalic acid (I)
6.7.6 CBZ/2,6-pyridinedicarboxylic acid (J)
6.7.7 CBZ/acetic acid solvate (K)
6.7.8 CBZ/formic acid solvate (L)
6.7.9 CBZ/butyric acid solvate (M)
6.7.10 CBZ/benzenesulfonate (N)
6.8 Discussion

61
62
62
63
63
64
64
64
65
65
66
66
66
67

Chapter 7- Conclusions

69

References

72

Appendices
Appendix A: Crystallographic Data for Polymorphic Structures A-D
Appendix B: Crystallographic Data for Model Compound Structures A-E
Appendix C: Crystallographic Data for Piracetam Structures A-B
Appendix D: Crystallographic Data for Carbamazepine Structures A-D
Appendix E: Crystallographic Data for Carbamazepine Structures E-I
Appendix F: Crystallographic Data for Carbamazepine Structures J-N

79
80
81
82
83
84
85

iii

List of Tables
Table 1.

Bond Energy Comparisons

5

Table 2.

Melting points of starting materials and structures, A-E

34

Table 3.

Melting points of starting materials and structures, A-B

43

Table 4.

Melting points of starting materials and structures, A-D

52

Table 5.

Melting points of starting materials and structures, E-I

62

Table 6.

Melting points of starting materials and structures, J-N

63

iv

List of Figures
Figure 1.

Supramolecular Homosynthon Examples

4

Figure 2.

Supramolecular Heterosynthon Examples

4

Figure 3.

Molecular Structure of BHA

13

Figure 4.

BHA Form I

13

Figure 5.

BHA Form II

14

Figure 6.

Molecular Structure of BHA-related Molecules

15

Figure 7.

Molecular Structure of Aspirin

16

Figure 8.

Centrosymmetric Aspirin Dimer

19

Figure 9.

Aspirin Form Comparison

20

Figure 10.

Primary Amide Homosynthon Motifs

22

Figure 11.

Primary Amide Dimer Motifs

24

Figure 12.

Primary Amide-Alcohol Heterosynthon Motifs

27

Figure 13.

Nicotinamide/ 3-Hydroxybenzoic acid

31

Figure 14.

Nicotinamide/ 4-Hydroxybenzoic acid

32

Figure 15.

Nicotinamide/ Gentisic acid

32

Figure 16.

Pyrazinamide/ Gentisic acid

33

Figure 17.

Acetamide/ Gentisic acid

34

Figure 18.

Molecular Structure of Piracetam

39

v

Figure 19.

Piracetam Homosynthon Motifs

40

Figure 20.

Piracetam/ Gentisic acid

41

Figure 21.

Piracetam/ 4-Hydroxybenzoic acid

42

Figure 22.

Molecular Structure of Carbamazepine

46

Figure 23.

Forms I and II of Carbamazepine

47

Figure 24.

Carbamazepine/ Benzoquinone

49

Figure 25.

Carbamazepine/ 4,4’-bipyridine

50

Figure 26.

Carbamazepine/ Cinnamic acid

51

Figure 27.

Carbamazepine/ Formamide solvate

51

Figure 28.

Carbamazepine/ Acetylsalicylic acid

55

Figure 29.

Carbamazepine/ 4-Aminobenzoic acid

56

Figure 30.

Carbamazepine/ 4-Aminobenzoic acid Hydrate

57

Figure 31.

Carbamazepine/ Trimesic acid

57

Figure 32.

Carbamazepine/ 5-Nitroisophthalic acid

58

Figure 33.

Carbamazepine/ 2,6-Pyridinedicarboxylic acid

59

Figure 34.

Carbamazepine/ Acetic acid solvate

60

Figure 35.

Carbamazepine/ Formic acid solvate

61

Figure 36.

Carbamazepine/ Butyric acid solvate

61

Figure 37.

Carbamazepine/ Benzenesulfonate

62

vi

Crystal Engineering of Novel Pharmaceutical Forms
Jennifer Anne McMahon
ABSTRACT
In the context of pharmaceutical development, it is abundantly clear that there is a
need for greater understanding and control of crystalline phases. The field of crystal
engineering is poised to address such issues and has matured into a paradigm for the
supramolecular synthesis of new compounds with desired properties.
Crystal structures are unpredictable by nature, however, the interactions that lead
to crystal formation are becoming much more predictable. By means of model compound
studies, the delineation of the hierarchy of hydrogen bonding between complementary
functional groups or supramolecular heterosynthons can be accomplished. Competitive
co-crystallization studies along with data extracted from the Cambridge Structural
Database (CSD) can be utilized in understanding the reliability of supramolecular
heterosynthons without the need for endless co-crystallization experiments. In effect, this
ability to understand supramolecular heterosynthons can allow crystal engineers to
rationally design co-crystals with a high rate of success.
It has been suggested that pharmaceutical co-crystals could play a significant part
in the future of API formulation since in principle they will outnumber pharmaceutical
salts, polymorphs and solvates combined.

vii

The focus of this thesis is the understanding of the primary amide functional
group and its hydrogen bonding capabilities; as well as the synthesis of model
compounds in order to develop a blueprint for the design of pharmaceutical co-crystals
using API’s that contain a primary amide functional group.

viii

Chapter 1
Introduction

1.1 Crystal Engineering
The term “crystal engineering” was introduced by R. Pepinsky in 1955 [1] and
was implemented in the context of organic solid-state photochemical reactions by G.M.J.
Schmidt in the 1960’s [2]. Today solid-state synthesis continues to represent an active
area of research in the context of crystal engineering [3].
Crystal engineering can be defined as “the application of the concepts of
supramolecular chemistry to the solid state with particular emphasis upon the idea that
crystalline solids are de facto manifestations of self-assembly” [4]. Consequently, crystal
structures can be regarded as the result of a series of weak but directional molecular
recognition events.
Crystal engineering has since grown into a form of supramolecular synthesis
using these directional molecular recognition events as the critical design element for the
generation of new compositions of matter with markedly different physical and chemical
properties [5].
The idea that molecular recognition lies in the complementarity of interacting
surfaces was first clearly formulated by Dutch chemist Emil Fisher, who proposed in
1894 that the enzyme and substrate fit together "like lock and key" [6]. A modern
1

definition of molecular recognition is the assembly of two molecules through molecular
functionalities that can be anticipated to interact with each other in an expected fashion.
These molecular recognition events have been termed supramolecular synthons [7]. The
ability to make use of these supramolecular synthons as building blocks in larger
assemblies lies in the understanding of the strength and reliability of these interactions as
well as how to reliably direct the self-assembly process.
Crystal engineered structures are designed from first principles and therefore can
consist of a wide range of chemical components as demonstrated by coordination
polymers [8], polymers sustained by organometallic linkages [9], and hydrogen bonded
organic networks [10].
The work of this thesis has focused upon a more recent application of crystal
engineering, which is to generate novel pharmaceutical compositions [11].
Pharmaceuticals were chosen because they are highly amenable to crystal engineering
studies due to the fact that the majority of API’s are crystalline solids. The benefits of
this include the physico-chemical stability of the crystalline solid state and the ease of
isolating a pure product [4].
What are the advantages of applying crystal engineering to pharmaceutical
development? Crystal engineering allows for the design of new compositions of matter
using existing pharmaceuticals, which allows for a much wider range of possible
pharmaceutical compositions than present methods such as ion-pairing (salt formation). It
has been suggested that pharmaceutical co-crystals could play a significant part in the
future of API formulation given that they, in principle, will outnumber pharmaceutical
salts, polymorphs and solvates combined.
2

The physical properties of interest for specific active pharmaceutical ingredients
(API’s) could be scientifically optimized by rational design rather than serendipitous
experimentation. In addition, preliminary indications show that a compound with
polymorphic tendencies could display a decreased propensity toward polymorphism as a
co-crystal, rather than a pure phase, although significant research is needed to support or
repudiate this argument [4].

1.2 Supramolecular Synthons
A supramolecular synthon is a reliable and well-defined linear connection
between molecular building blocks. Synthons are formed by the assembly of two
molecules through molecular functionalities that interact with each other in a predictable
fashion. Self-complementary functional groups, such as carboxylic acids, amides, and
alcohols contain both a hydrogen bond donor and acceptor and are therefore capable of
forming supramolecular homosynthons (fig. 1). Other functionalities, which contain only
hydrogen bond donors or acceptors, do not have this capability. However, all
functionalities are capable of forming supramolecular heterosynthons with other
complementary functional groups (fig. 2).
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Figure 1. Supramolecular Homosynthon Examples; (a) Carboxylic acid dimer (b) Primary amide dimer (c) Alcohol homosynthon.

Groups that are capable of forming supramolecular synthons include, but are not
limited to; acids (carboxylic, sulfonic, phosphonic, and boronic), primary and secondary
amide, alcohol, amino-pyridine, ketone, aldehyde, ether, ester, primary and secondary
amine, aromatic nitrogen, cyano, imine, nitro, sulfonyl, sulfoxide, sulfonamide, water,
and ions such as Cl- and Br-. Also, competition between intermolecular interactions can
occur within a structure that contains a multiple number of functional groups capable of
hydrogen bonding.
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Figure 2. Supramolecular Heterosynthon Examples; (a) Carboxylic acid/ Primary amide (b) Carboxylic acid/ Pyridine (c) Cyano/
Alcohol.
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Even though hydrogen bonding is considered a weak interaction (table 1), it is the
most important of all directional intermolecular interactions [12]. It is of tremendous
importance to the structure, function, and dynamics of a vast number of chemical systems
[13]. Hydrogen bonds result from the interaction of an electropositive hydrogen atom on
one molecule with a lone pair of an electronegative atom on a second molecule. The
result is highly selective and directional interactions that are also responsible for the
formation of highly ordered crystalline solids [5c]. This makes them highly amenable to
crystal engineering.
Table 1. Bond Energy Comparison

Interaction type
Covalent bond
Hydrogen bond
Dipole-dipole forces
van der Waals forces

Energy (kJ/mol)
100 - 900
10 - 40
19
0.5 – 5

Jacob Israelachvili, Intermolecular & Surface Forces (2nd edition, Academic Press, 1992)

Understanding supramolecular homosynthons and heterosynthons; i.e. their
probability of formation, reliability, and hierarchy in competitive situations represents an
opportunity for the synthesis of co-crystals, and therefore, the design of unlimited new
compositions of matter with modified solid-state physical properties.

1.3 Co-crystals
What are co-crystals? Co-crystals are multiple component structures whose
components interact by hydrogen bonding or other weak intermolecular interactions
rather than by ion pairing. A valuable approach to understanding and designing cocrystals is to employ supramolecular synthesis, in particular exploitation of
5

supramolecular heterosynthons [11,14]. In the context of co-crystals, supramolecular
synthesis is a relatively low-risk strategy, because the approach employs principles of
molecular recognition and self-assembly rather than creating covalent bonds. A detailed
understanding of the supramolecular chemistry of the functional groups present in a given
molecule is the first step in designing a co-crystal since it facilitates selection of
molecules that contain the appropriate complementary functional groups. Herein, these
complementary molecules will be referred to as co-crystal formers.
While co-crystals can be easily obtained under the proper conditions, this does not
mean that their synthesis and isolation is nonetheless routine. Solvent selection can be
critical in obtaining a particular co-crystal; however the role of solvent in the nucleation
of crystals and co-crystals remains poorly understood [15]. In addition, undesired
products such as solvates, hydrates, polymorphs, or pure compounds can often result
from co-crystallization experiments.
Synthesis of a co-crystal from solution might be thought of as counterintuitive
since crystallization is such an efficient and effective method of purification and it is used
extensively in the fine chemicals and pharmaceutical industries for such a purpose.
However, if different molecules with complementary functional groups result in
hydrogen bonds that are energetically more favorable than those between like molecules
of either component, then co-crystals are likely to be favored.
Techniques used for the characterization of co-crystals include single crystal x-ray
diffraction, infrared spectroscopy, differential scanning calorimetry, thermogravimetric
analysis, melting point apparatus, and powder x-ray diffraction.

6

The prospective impact of co-crystals is broad-ranging as suggested by recent
studies which indicate that co-crystals can play a role in solvent-free organic synthesis
(photodimerization of olefins using linear templates) [16], for design of host−guest
systems [17], in modification of photographic films [18], for reformulation of active
pharmaceutical ingredients (APIs) [4,11,19] and for generation new classes of NLO
materials [20].

1.4 Pharmaceutical Co-crystals
Co-crystals are currently of interest to several research groups [21] and have been
known for decades [22], however, their systematic design and application to active
pharmaceutical ingredients (API’s) has not.
The complex nature of APIs means that they inherently contain peripheral
functional groups that engage in molecular recognition events. Indeed, it is the very
presence of these functional groups that affords biological activity but also provides an
ability to engage in more than one supramolecular event with itself, a solvent molecule or
co-crystal former, thereby forming polymorphs, solvates or co-crystals, respectively.
The preferred form of most APIs is a crystalline solid since they are of high
purity, high stability and are easy to handle and characterize during the numerous stages
of drug development. The use of crystalline solids in pharmaceutical formulations is
preferred over the metastable amorphous form in order to limit physical and chemical
instability of the marketed drug [23]. Crystalline API’s are also easier to isolate and
purify.

7

Herein pharmaceutical co-crystals will be defined as being a subset of a broader
group of multi-component crystals that also includes salts, solvates, hydrates, clathrates,
and inclusion crystals. In a supramolecular context, solvates/hydrates and pharmaceutical
co-crystals are related to one another in that at least two components of the crystal
interact by hydrogen bonding and, perhaps, other noncovalent interactions rather than by
ion-pairing. Both neutral compounds and salt forms have the potential to be solvated (i.e.
interact with solvent molecules) or co-crystallized (i.e. interact with a co-crystal former).
Solvate molecules and co-crystal formers can include organic acids or bases that remain
in their neutral form within the multi-component crystal. The primary difference lies in
the physical state of the isolated parent components: if one component is a liquid at room
temperature, the crystals are referred to as solvates; if both components are solids at room
temperature, the products are referred to as co-crystals. Upon first glance these
differences may seem insignificant; however, they can profoundly impact the stability,
preparation, and development of products.
Another advantage of pharmaceutical co-crystals is that they can be rationally
designed unlike solvates, which often occur unanticipated from solution. In addition,
while there are a limited number of solvents and counter-ions, potential co-crystal
formers such as compounds from the FDA’s GRAS list, sugars, natural products,
vitamins, and flavorings are much more numerous. This allows for the design of new
compositions of matter using existing pharmaceuticals, which opens up a wide range of
possible pharmaceutical compositions.

8

1.5 Polymorphism
The ability of a molecule to form both homosynthons and heterosynthons can also
lead to a phenomenon known as polymorphism. Polymorphism is the ability of a
substance to exist in more than one crystalline form [24]. Although polymorphs contain
the same chemical composition, their solid-state properties generally differ as a
consequence.
Polymorphism is a major concern for the pharmaceutical industry for many
reasons. Properties such as solubility, bioavailability, hygroscopicity, stability, and
toxicity of an API are dependent on the polymorphic state. It is essential that the desired
form be reproducible and that it can remain stable during production and marketing.
Polymorphism opens up an avenue for studies of structure-property relations [25]
since the only variable between polymorphs is that of the crystal packing and/or
conformation. The chemical composition does not change. The physical properties of
organic materials are inherently dependent upon not only the nature of the molecules but
also the nature in which they interact with each other in the solid state. The variation of
physical properties in a polymorphic system can give insight into the role of
intermolecular interactions. However, the fact remains that polymorphs cannot be
designed and often are found serendipitously.

1.6 Cambridge Structural Database
Started in 1965, the Cambridge Structural Database (CSD) [26] is an important
tool for the solid-state chemist. As of the February 2005 update, the CSD (v. 5.26)
contains 338,445 structures. The database records bibliographic, 2D chemical and 3D
9

structural information for organocarbon compounds studied by X-ray and neutron
diffraction. Given the large amount of data available, there are many research
applications including conformational analysis, structural correlation, and statistical
analysis, studies of crystal packing and intermolecular interactions, crystal engineering,
polymorphism and crystal structure prediction [27]. The CSD allows statistical analysis
not only of molecular structure but also of packing motifs. Functional groups that are
common or of special interest can therefore be studied in terms of how they associate
with themselves or other functional groups.
In order to properly design a supramolecular structure, one must understand what
intermolecular operations are possible, and be able to predict which will occur. Etter
formulated a set of hierarchy rules for hydrogen bonding in systems with multiple
functionalities that are capable of hydrogen bonding that is based upon best (strongest)
donor to best acceptor, second best donor to second best acceptor [28].
Competitive studies on the hydrogen bonding preferences of numerous functional
groups using co-crystals are underway in several research groups [10c, 29]. These
competitive studies are the start to delineation of the hierarchy involved in the
supramolecular interactions between these functional groups. This will allow for the
ability to predict with a higher degree of accuracy which molecular recognition events
will occur between specific functional groups and increase the number of designed cocrystals.

10

Chapter 2
Polymorphism in Single Component Systems

2.1 Introduction
Pharmaceutical manufacturers have taken notice since the first case of
polymorphism with dramatically different biological activity between two forms of the
same drug, chloramphenicol palmitate (CAPP), was discovered [30]. Form A of the
broad-spectrum antibiotic is the most stable and the marketed form. Form B has been
shown to have an eightfold higher bioactivity than Form A. The possibility of fatal
dosing exists if the unwanted polymorph were to be administered [31].
Commercial drug formulations have been taken off the market due to an
unexpected appearance of an undesired polymorph. In 1998, Abbott Laboratories had to
pull the HIV protease inhibitor Ritonavir (Norvir) off the market because a new
polymorphic form of the drug, Form II, had popped up in the manufacturing process.
This new form was less than 50% as soluble as the marketed form and compromised the
oral bioavailability of the capsules. The drug had to be reintroduced in a liquid form due
to the inability to regenerate the original form [32].
Polymorphs are also established in law as discrete materials, which, when
considering the intellectual property implications, can be extremely important. The best
example of this is the case of Ranitidine hydrochloride (Zantac), an ulcer drug.
11

Glaxo Wellcome, now GlaxoSmithKline (GSK), introduced Zantac in 1981 and for a
decade it was the world’s best selling prescription drug. GSK’s patent for Zantac
designated Form II of the drug as the form that would be marketed. Novopharm, a
Canadian pharmaceutical company, wished to market a generic form of the drug using
Form I. GSK brought an action suit against Novopharm claiming that any process to
manufacture Form I would result in some Form II being present, therefore infringing on
GSK’s patent. The court ruled in favor of Novopharm and GSK lost its monopoly on
Zantac [5c].

2.2 BHA (antioxidant)
2.2.1 Description
Butylated hydroxy anisole (BHA; 3-tert-butyl-4-hydroxy anisole) (fig. 3)
represents a small molecule that contains flexible groups and hydrogen bond donor and
acceptor sites that has not been structurally characterized even though its use as an
antioxidant in solid dosage forms is ubiquitous throughout the pharmaceutical industry.
The ability of BHA to effectively retard degradation varies depending on concentration,
choice of excipients and processing methods, and storage conditions [33]. The behaviour
of BHA is complex. In some cases, it appears to cause oxidation of the drug in certain
formulations while protecting it in others, even at the same BHA loading [34]. The
primary mode of action of BHA is well known [35]; it becomes a free radical by donating
a hydrogen atom to a free radical. The BHA radical is stabilized by resonance and
interferes with the propagation step of the radical reaction, thereby retarding the
degradation.
12

O

OH
Figure 3. Molecular structure of 3-BHA.

We have reported the single crystal x-ray characterizations of both the
commercially available form of 3-BHA and a new polymorph designated herein as form I
and form II, respectively [36].

2.2.2 Synthesis and Characterization
Form I of BHA (A) forms rod-like triclinic crystals (fig. 4). Molecules of BHA
self-assemble via OH…ether hydrogen bonds. This head-to-tail interaction results in a 4fold helix, which intertwines with a second helix to form a double helical structure
similar to that of DNA. The O…O distances of 2.707, 2.710 and 2.740 Å are within
expected ranges for such interactions. The t-butyl groups orient outward meaning that
the exterior surface of the helix is hydrophobic. Form I melts at 61ºC and the calculated
density is 1.158 g/cm3.

Figure 4. BHA Form I; A single 4-fold helix of the BHA double helix.
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Form II (B) (fig. 5) exists as block-like trigonal crystals. It also consists of
supramolecular structures that are the result of head-to-tail OH…ether hydrogen bonds
(O…O = 2.778 Å). However, form II is a discrete species that results from the selfassembly of 6 molecules and, unlike form I, all t-butyl groups face inward. Form II melts
at 64.8ºC and the calculated density, 1.136 g/cm3, is slightly lower than that of form I.

Figure 5. BHA Form II; The hexameric supramolecular structure exhibited by Form II.

2.2.3 Discussion
The OH…ether supramolecular synthon that occurs in these BHA polymorphs
represents an example of a one-point interaction and therefore it should be unsurprising
that the angle of interaction between adjacent molecules can vary enough to generate
such different supramolecular structures as in Forms I and II of BHA. However, it is
perhaps surprising that it occurs instead of the OH…OH supramolecular synthon. Indeed,
a CSD [37] survey revealed the presence of 693 crystal structures that have both a
hydroxy and methoxy group. Of these, only 57 (8%) were found to contain the
OH…ether interaction.
The crystal packing of a number of BHA-related molecules (fig. 6) was therefore
analyzed to compare hydrogen bonding motifs. In simple alcohols such as methanol,
14

ethanol and t-butanol, OH…OH…OH interactions afford zigzag chains or helices. Phenol
and 2-methylphenol form OH…OH 3-fold helices, whereas 4-methoxyphenol forms an
OH…OH zigzag chain. A similar situation was observed in 4-bromo-phenol, which forms
a 4-fold helix via OH…OH hydrogen bonds. It is interesting to note that the methoxy
group in 4-methoxyphenol does not interfere with the alcohol-alcohol interactions and is
excluded from any involvement in hydrogen bonding. However, for 2,6-di-t-butyl-4methoxyphenol, an OH…ether hydrogen bond occurs rather than an OH…OH interaction
and in 4-bromo-2,6-di-t-butylphenol there are no hydrogen bond interactions. Therefore,
there is precedence for adjacent t-butyl groups to sterically hinder OH…OH interactions
and thereby facilitate OH…ether hydrogen bonds, as is the case for both forms of BHA.
OH

OH

OH

OH

OMe

Br

CH3

OH
(ch3)3c

OH
c(ch3)3

(ch3)3c

OMe

c(ch3)3

Br

Figure 6. Molecular structure of BHA-related molecules; Top: phenol, 2-methylphenol, 4-methoxyphenol, 4-bromophenol; Bottom:
2,6-di-tert-butyl-4-methoxyphenol, 4-bromo-2,6-di-tert-butylphenol.

2.3 Aspirin (API)
2.3.1 Description
Aspirin (acetylsalicylic acid) is one of the most widely used drugs in the world
and has been shown to be effective as an anti-inflammatory, anti-pyretic, and anti15

rheumatic agent as well as in reducing the risks of heart attack and stroke. Aspirin (fig.
7) is a molecule that needs little introduction. It has a long and varied history that begins
with the use of sodium salicylate as a painkiller in the 1800’s. The main drawback of this
drug was irritation to the stomach lining. In 1853, a French chemist named Charles
Frederic Gerhardt tried to improve on sodium salicylate by combining it with acetyl
chloride [38]. Although he actually succeeded in producing a new compound that was
less irritating to the stomach, he saw little promise for the compound and abandoned his
discovery.

O

OH
O

O

Figure 7. Molecular structure of Aspirin.

In 1897, Felix Hoffman, a German chemist who worked for Bayer, began
searching for a less-irritating substitute for salicylic acid and synthesized a stable
derivative known as acetylsalicylic acid. By the turn of the century, it became the number
one drug worldwide [39].
Despite the fact that aspirin has been widely studied and repeatedly crystallized
under a variety of conditions, only one crystalline form has been structurally
characterized. Form I of aspirin (C) was first determined by Wheatley [40] in 1964, and
later refined by Kim et al. [41] in 1985. In 2002, Wilson [42] determined the structure by
neutron single crystal diffraction (CSD refcode: ACSALA02). The crystal packing of the
known form of aspirin consists of hydrogen bonded centrosymmetric carboxylic acid
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dimers [O...O 2.635 Å] as well as centrosymmetric ester dimers [O...O 3.553 Å] thereby
forming a 1D extended chain.
The first report of a potential aspirin polymorph was published in Science in 1968
by Tawashi [43]. Observations were based on x-ray diffraction patterns and the
dissolution rates of different formulations of aspirin; form I from ethanol and form II
from n-hexane, however, unequivocal evidence for polymorphism could not be obtained.
In the 1970’s and 80’s, several experimental studies were carried out to determine
if aspirin did indeed exhibit polymorphism [44]. Although many of these studies
reported considerable variations in the physical properties of aspirin (i.e., morphology,
dissolution rate, heats of fusion, melting point, etc.), no conclusive evidence for the
existence of a polymorph was revealed.
The considerable debate about whether or not experimental observations have
confirmed the existence of a second polymorph of aspirin has driven chemists to find
other ways to answer this question. In 1988, Etter, et al. first touched on the possibility
of molecular modeling by identifying unknown low energy conformers, predicting their
crystal structures, and consequently devising experimental conditions which are most
likely to produce the desired form [45]. Although molecular modeling for crystal
structure prediction is still in the early stages of development, computational studies have
proved useful in aiding in the characterization of polymorphs from powder X-ray data, as
well as in providing insight into the types of packing that may be adopted by a given
molecule [46].
According to Dunitz [47], advances in technology should lead to improved
methods of obtaining data such as the range of thermodynamic stability for hypothetical
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structures, vibrational frequency measurements for individual molecules, and better
methods of converting potential energies to free energies. From only a molecular
formula, a list of 10-20 crystal structures within an energy window of a few kJ mol-1 can
be obtained, which, in theory, will most likely contain all observable polymorphs.
The discovery of this once elusive new form of aspirin, herein referred to as
Form II, was isolated during co-crystallization experiments with aspirin and other
compounds containing primary amides [48]. The expected outcome of the experiment
was a co-crystal containing the acid-amide supramolecular heterosynthon. Indeed, cocrystallization of aspirin with carbamazepine did result in the expected 1:1 co-crystal, the
structure of which is described in Section 6.6.1 (fig. 27) of this thesis.
Form I is kinetically stable at 100° K, however, Form II is relatively unstable
and converts back to Form I at ambient conditions. Both forms contain a centrosymmetric
carboxylic acid dimer (fig. 8), however, there is a slight difference in the torsion angle
defined by the acetyl and carboxylic acid groups [O…O Form I: 164.0°; O…O Form II:
173.1°]. There are clear differences in the crystal packing of adjacent dimers. Form I
assembles into 1D chains sustained by alternating carboxylic acid and acetyl group
dimers, whereas Form II assembles into chains of carboxylic acid dimers that are
connected via weak catemeric C_H…O hydrogen bonds [C…O: 3.85(2) Å, 164.0°]
between the methyl groups and the carbonyl oxygen of the acetyl group.
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Figure 8. Centrosymmetric Aspirin Dimer.

2.3.2 Synthesis and Characterization
We report herein single crystal X-ray characterization of a new polymorph of
aspirin (C9H8O4; mw = 180.16). The crystal packing in Form II (D) is remarkably
similar to that of Form I (C) (fig. 9) with the cell parameters differing only by a 15.6˚
change in the β angle. The centrosymmetric carboxylic acid dimer is intact; however, the
change in β interrupts the formation of the centrosymmetric ester dimer. The ester
carbonyl in Form II is bound by a weak C_H…O hydrogen bond to the methyl group of a
neighboring ester group [C...O 3.343 Å].
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Figure 9. Aspirin Polymorph Comparison; Left: Form I consists of 1D chains of alternating acid and acetyl dimers; Right: Form II
assembles into chains of carboxylic acid dimers that are connected via catemeric C-H…O hydrogen bonds.

Form II of aspirin exists as thin monoclinic plates that were synthesized from
binary co-crystallization experiments with the following molecules; acetamide and
levetiracetam; both of which contain a primary amide functional group. The cocrystallization experiments were carried out using a 1:1 stoichiometry of aspirin and cocrystal former dissolved over heat in acetonitrile. The colorless plates formed in
approximately 3 days via slow evaporation and were preserved in a small amount (<0.10
mL) of the mother liquor until put on the diffractometer. Form II was characterized by
melting point, IR, DSC, simulated X-ray powder diffraction and single crystal x-ray
diffraction. (for crystallographic data, see Appendix I)
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2.4 Discussion
Aspirin is an excellent candidate for studies on polymorphism. It has been studied
and crystallized extensively for many years; however, a new polymorph was found only
after co-crystallization experiments using primary amides as potential co-crystal formers.
Its ability to exhibit polymorphism has been speculated on since 1968 [43,49].
Depending on one’s point of view, polymorphism can either be viewed as a
nuisance or an opportunity. The potential effects of an unintended polymorph on the
pharmaceutical industry can be daunting. First and foremost, the bioavailability of a
marketed drug depends entirely on the polymorphic form present in the drug’s
formulation. Crystallization of an inadvertent polymorph can mean months of production
downtime, loss of revenue, and even life-threatening consequences for the consumer.
Also, the ability to patent new polymorphs as discrete materials can have give
competitors legal loopholes that can have a large effect on the profitability of a new drug.
On the other hand, a thorough understanding of polymorphism gives companies a
distinct advantage in bringing new drugs to market. Polymorphic forms can be used to
maximize a drug’s chemical and physical stability, hygroscopicity, solubility,
bioavailability and/or manufacturability. Also, the ability to identify new crystal forms of
a drug can provide a higher level of intellectual property protection.
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Chapter 3
Primary Amides

3.1 Primary Amide Homosynthons
In the context of primary amides, early research on hydrogen bonding is
exemplified by Schmidt’s seminal work in the 1960’s [50]. Primary amides illustrate
remarkable diversity in their ability to form hydrogen bonds due to the fact that they
contain two hydrogen bond donors (NH2) and an acceptor (CO) [51]. They exhibit two
basic modes of self-organization to form supramolecular homosynthons: the dimer and
the catemer (fig. 10).
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Figure 10. Primary Amide Homosynthon motifs: a) primary amide dimer; b) primary amide catemer.

A Cambridge Structural Database (CSD) survey of compounds in which a
primary amide is the only functional group capable of forming strong hydrogen bonds
was conducted in order to understand the statistics of supramolecular homosynthon
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formation of primary amides [52]. This survey revealed the percentage of occurrence and
the structural parameters of supramolecular homosynthons involving a primary amide.
Contact limits for each interaction were determined from histograms obtained by
applying contact distances well beyond the sum of the van der Waals radii of the acceptor
and the donor atoms. The survey revealed that there are 1151 crystal structures in which
at least one primary amide functional group is present. Three hundred ninety of these
structures (34%) exhibit the dimer motif whereas 261 structures (23%) were found to
exhibit the catemer. The average N···O distance of N−H···O hydrogen bond for the dimer
and catemer are 2.95(5) and 2.96(8) Å respectively. Many of these structures contain
other functional groups that can compete for the hydrogen bonding capabilities of the
primary amide; consequently the remaining 500 of the 1151 structures (43%) are those
that contain supramolecular heterosynthons, which will be discussed in 3.2.
There are only 101 primary amide structures in which competing hydrogen bond
donor and/or acceptor groups are absent. The percentage of occurrence of the dimer and
catemer increases to 82% (83) and 16% (16) respectively in these structures, while two
structures (2%) contained both a dimer and catemer.
The primary amide dimer has the potential to form larger assemblies because it
has both donors and acceptors at its periphery. Three distinct patterns are possible:
discrete, catenated and shallow glide motif (fig. 11). In the discrete dimer, the antioriented NH does not engage in further hydrogen bonding, most frequently because of
steric hindrance. The catenated dimer, sometimes referred to as an amide tape or ribbon,
is a chain of translational related dimers linked along a 5.1 Å short axis by N−H···O
bonds. The third pattern is the shallow glide motif in which the amide dimers are
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hydrogen bonded to four other dimers through exterior hydrogen bonding. The dihedral
angle between the central dimer and the adjacent dimers in these structures is highly
variable. Of the 83 structures found containing a primary amide dimer in the absence of
other competing donors and/or acceptors, the percentage of occurrence for each type of
pattern is; discrete (22%), catenated (23%) and shallow glide (55%).
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Figure 11. Primary amide dimer motifs: a) discrete; b) catenated; c) shallow glide motif.

3.2 Primary Amide Heterosynthons
Given that 500 of the 1151 total primary amide structures did not contain a
primary amide homosynthon, subsequent searches focused on supramolecular
heterosynthons involving the primary amide moiety. Primary amides can form a diverse
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range of supramolecular heterosynthons with a number of other complementary
functional groups such as chloride, cyano, carboxylic acid and alcohol.
The primary amide-chloride ion heterosynthon (N−H···Cl−) represents an example
of a charge-assisted one-point hydrogen bond and was found to occur in the highest
percentage for primary amide heterosynthon formation. The 38 structures containing both
groups reveal 29 crystal structures (76%) that exhibit the primary amide-chloride ion
supramolecular heterosynthon and 3 structures (8%) that form an exterior heterosynthon
through the anti-oriented NH of the amide dimer. Six structures (16%) contain a primary
amide heterosynthon with a functional group other than the chloride ion.
There were no structures found that exclusively exhibited an amide homosynthon.
The amide-chloride ion heterosynthon was found to occur within the range 3.10-3.60 Å
(N···Cl-) with an average hydrogen bond distance of 3.34(8) Å.
The primary amide-cyano supramolecular heterosynthon (N−H···NC) is another
example of 1-point recognition. There are 51 crystal structures in which both primary
amide and cyano groups are present. Twenty-six of these structures (51%) contained the
amide-cyano supramolecular heterosynthon. Five of these structures (10%) exhibit the
primary amide-cyano supramolecular heterosynthon exclusively with no primary amide
homosynthon present. In approximately 41% of the 51 structures containing this
supramolecular heterosynthon, the cyano group hydrogen bonds to the anti-oriented NH
of the amide dimer or catemer. In the remaining 25 structures, 18 contain an amide
homosynthon, and 7 contain an amide involved in a heterosynthon with another
functional group. The amide-cyano supramolecular heterosynthon was found to occur
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within the range of 3.00-3.30 Å (N···N), with a mean hydrogen bond distance of 3.15(9)
Å.
The primary amide-carboxylic acid heterosynthon has been previously utilized
[50] in forming co-crystals and appears to be a robust and reliable supramolecular
heterosynthon. There are 125 crystal structures in which both a carboxylic acid and a
primary amide moiety are present; 53 of these (42%) exhibit the two-point primary
amide-carboxylic acid supramolecular heterosynthon whereas only 5 structures (4%)
exhibit an acid homosynthon and 49 structures (39%) form an amide homosynthon.
Seventy percent of the 53 structures containing an acid-amide supramolecular
heterosynthon are exclusive of any acid or amide homosynthon (dimer or catemer). Since
this supramolecular heterosynthon is a two-point recognition event, there are two ranges
corresponding to O−H···O and N−H···O interactions. The O···O range for O−H···O
hydrogen bond is 2.40-2.80 Å and the mean hydrogen bond distance is 2.56(6) Å. This
distance is shorter than that of the carboxylic acid homosynthon (dimer or catemer), for
which the O−H···O range is 2.40-3.00 Å with a mean of 2.65(3) Å. The N···O range for
(amide)N−H···O(acid) hydrogen bond was found to be 2.80-3.25 Å with a mean of
2.96(8) Å, which is longer than that observed for the amide dimer 2.75-3.15 Å [mean
2.95(5) Å] or catemer 2.75-3.20 Å [mean 2.96(8) Å]. These data suggest that the amide
carbonyl could be a stronger H-bond acceptor than the acid carbonyl.
The ability of alcohols to operate as either hydrogen bond donors and/or acceptors
[53], leads to two very different heterosynthons with primary amides (fig. 12). The
(amide)O···O(alcohol) supramolecular heterosynthon occurs in 110 (43%) of the 255
crystal structures in which both a primary amide and an alcohol moiety is present,
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whereas 78 crystal structures (31%) exhibit the primary amide homosynthon and 60
structures (24%) form the alcohol homosynthon. Thirty seven percent of the 110
structures containing the heterosynthon are exclusive of either primary amide or alcohol
homosynthons. The O−H···O heterosynthon exhibits a range 2.60-3.00 Å with a mean of
2.75(8) Å.
A similar trend is observed in the case of the (amide)N−H···O(alcohol) synthon
(fig. 12). One hundred twelve out of the 255 total structures (44%) were found to contain
an amide NH-alcohol supramolecular heterosynthon, thirty eight percent of which occur
exclusive of amide or alcohol supramolecular homosynthons. The
(amide)N−H···O(alcohol) distance was found to occur within the range 2.73-3.20 Å
(N···O), with a mean of 3.00(9) Å.
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Figure 12. Primary Amide-Alcohol Heterosynthon Motifs: a) amide carbonyl/alcohol; b) amide amine/alcohol.

3.3 Discussion
The first step in generating co-crystals is a detailed understanding of the
supramolecular chemistry of the functional group present in given molecule. A CSD
survey was conducted in order to understand the statistics of supramolecular
homosynthon and heterosynthon formation of primary amides. Primary amides, which
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contain two hydrogen bond donors (NH2) and an acceptor (C=O), demonstrate a
remarkable ability to form hydrogen bonds [51]. This survey has shown that the
occurrence of the primary amide dimer drops from 82% in structures where only a
primary amide moiety is present to 34% when one or more complementary functional
groups are involved. Identification of reliable supramolecular heterosynthons from an
analysis of the functional groups that inhibit primary amide dimer formation can then
facilitate the selection of appropriate co-crystal formers for the generation of co-crystals.
Such a strategy was employed using both model compounds and pharmaceutical
molecules containing a primary amide moiety as a result of this analysis, the details of
which are revealed in the following chapters of this thesis.
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Chapter 4

Model Compounds
4.1 Description
CSD surveys reveal that primary amides seem to favor heterosynthon formation
over that of the homosynthon motifs when certain complementary groups are also
present. This understanding of self-assembly involving primary amides facilitates a
rational approach to the design of co-crystals that are sustained by hydrogen bonding. In
particular, co-crystal formers can be selected based upon our knowledge of the statistical
probability of the occurrence of a particular supramolecular heterosynthon. Co-crystals
are likely to be formed if the groups that sustain a robust supramolecular heterosynthon
are in different molecules. However, the situation in real molecules, especially
pharmaceuticals, is often more complicated since there might be several potential
supramolecular heterosynthons. Through model compounds, the hydrogen bonding
preferences of common functional groups can be studied and applied to design and
synthesize co-crystals for a number of uses. Compounds A-E represent model
compounds in this context since they represent co-crystals in which there is a competition
between multiple supramolecular homosynthons and supramolecular heterosynthons.
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4.2 Strategy
A model compound study was done to in order to delineate the hierarchy of the
hydrogen bonding in co-crystals in which there is a competition between multiple
supramolecular homosynthons and supramolecular heterosynthons. The functional groups
of interest in the study are primary amide, carboxylic acid, aromatic nitrogen, and
alcohol.

4.3 Structures
4.3.1 nicotinamide / 3-hydroxybenzoic acid 1:1 (A)
A contains an alcohol moiety which is capable of competing with the acid moiety
for the pyridine group because it is unable to form an intramolecular hydrogen bond. The
CSD reveals that supramolecular heterosynthon occurrence for an acid-pyridine is 63%
whereas alcohol-pyridine occurs in 50% of the structures in which both groups are
present. The presence of an alcohol-nitrogen hydrogen bond would presumably free the
carboxylic acid moiety to form an acid-amide heterosynthon.
The crystal structure of A reveals that the alcohol does indeed hydrogen bond to
the pyridine moiety and the amide-acid supramolecular heterosynthon is formed. Each
amide-acid supramolecular heterosynthon is hydrogen bonded to four other amide-acid
dimers through (alc)O−H···N(amine) [O···N 2.693(2) Å] and amide N−H···O [N···O
2.943(2) Å] hydrogen bonds (fig. 13). The four exterior-bonding pairs are situated at
approximately a 90º angle, thereby generating a 2D network. The O−H···O [O···O
2.593(2) Å] and (amide)N−H···O(acid) [N···O 2.934(2) Å] hydrogen bond lengths for the
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amide-acid supramolecular heterosynthon are in the expected range and compare closely
to mean values of 2.56(6) Å and 2.96(8) Å respectively.

Figure 13. Nicotinamide / 3-hydroxybenzoic acid 1:1 co-crystal.

4.3.2 Nicotinamide / 4-hydroxybenzoic acid 1:1 (B)
Similarly to A, complex B (fig. 14) also contains an alcohol moiety capable of
competing with the acid group for the pyridine. The crystal structure of B also contains
an alcohol-pyridine interaction, as well as an amide-acid supramolecular heterosynthon.
In A, single amide-acid dimers are formed, however in B, the amide-acid dimers form a
tetrameric motif, presumably due to the position of the hydroxyl group on the acid. The
alcohol-pyridine hydrogen bond length is 2.725(2) Å [O···N]. The O−H···O [O···O
2.613(2) Å] and (amide)N−H···O(acid) [N···O 2.902(2) Å] hydrogen bond lengths for the
amide-acid supramolecular heterosynthon are in the expected range, and the amide antioriented N−H···O(acid) bond that connects the two dimers exhibits an N···O distance of
2.942(2) Å.
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Figure 14. Nicotinamide / 4-hydroxybenzoic acid 1:1 co-crystal.

4.3.3 Nicotinamide / gentisic acid 1:1 (C)
Structure C (fig. 15) contains the same functional groups as A and B, with the
addition of an ortho-substituted (intramolecularly bonded) hydroxyl group. In this case,
the supramolecular synthons are entirely different. The acid-pyridine OH···N
supramolecular heterosynthon is formed [O···N 2.575(5) Å], and the primary amide is
hydrogen bonded to three alcohol groups [O···O 2.688(5) Å; Nsyn···O 2.942(5) Å; Nanti···O
2.916(5) Å]. The lone interaction to the acid carbonyl is with the ortho-substitued
alcohol group which exhibits a hydrogen bond length of 2.600(5) Å.

Figure 15. Nicotinamide / gentisic acid 1:1 co-crystal.
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4.3.4 Pyrazinamide / gentisic acid 1:1 (D)
D is another example of a co-crystal that exhibits the amide-acid and alcoholpyridine supramolecular heterosynthons. The molecules in D (fig. 16) form a tetrameric
unit that consists of two molecules of each component that form two acid-amide
heterosynthons connected by alcohol O–H···N interactions at the periphery of the
supermolecule. Each tetramer is bridged to four others via hydrogen bonds between
alcohol moieties and anti-oriented amide NH’s that are not involved in the amide-acid
supramolecular heterosynthon (fig. 16). The O–H···O [O···O 2.597(2) Å] and N–H···O
[N···O 2.935(2) Å] hydrogen bond lengths for the amide-acid heterosynthon are within
the expected ranges.

Figure 16. Pyrazinamide / gentisic acid 1:1 co-crystal.

4.3.5 Acetamide / gentisic acid 1:1 (E)
E is a 1:1 complex (fig. 17), which is dominated by the amide-acid
supramolecular heterosynthon, as there is no pyridine moiety available to compete for the
acid. The O–H···O [O···O 2.607(1) Å] and N–H···O [N···O 2.949(2) Å] hydrogen bond
lengths for the amide-acid supramolecular heterosynthon are within the expected ranges.
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The alcohol moieties link each dimer through interactions with both the amide carbonyl
[O···O 2.732(1) Å] and the anti-oriented NH [N···O 2.950(2) Å].

Figure 17. Acetamide / gentisic acid 1:1 co-crystal.

4.4 Synthesis and Characterization
Melting points for each structure are presented in Table 2 along with melting
points for starting materials.
Table 2. Melting points of starting materials and model co-crystals, A-E.

Co-crystals
A. Nicotinamide / 3-hydroxybenzoic acid (1:1)
B. Nicotinamide / 4-hydroxybenzoic acid (1:1)
C. Nicotinamide / gentisic acid (1:1)
D. Pyrazinamide / gentisic acid (1:1)
E. Acetamide / gentisic acid (1:1)

Starting Materials [ºC]
130-133
203
130-133
217
130-133
205
189-191
205
81
205

Co-crystal [ºC]
123-125
185-186
171-172
164-166
141

4.4.1 Nicotinamide / 3-hydroxybenzoic acid 1:1 (A)
Synthesis: Colorless crystals were obtained within three days via slow evaporation
of a solution containing nicotinamide (0.015 g, 0.123 mmol) and 3-hydroxybenzoic acid
(0.017 g, 0.123 mmol) dissolved in 1 ml of acetonitrile.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix B.
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Melting Point: (Mel-temp®) 123-125˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3404 cm-1 (Amide NH
stretch); 3205 cm-1 (C-H stretch, alkene); 1662 cm-1 (C=O); 1595 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). All powder data were collected over an angular range of 3 to 40 theta in
continuous scan mode using a stepsize of 0.02 theta and a scan speed of 2.0 /min unless
otherwise noted. XPD analysis (experimental): 7.480, 16.539, 19.263, 23.538, 26.400.
4.4.2 Nicotinamide / 4-hydroxybenzoic acid 1:1 (B)
Synthesis: Colorless crystals were obtained within 3 days via slow evaporation
of a solution containing nicotinamide (0.015 g, 0.123 mmol) and 4-hydroxybenzoic acid
(0.017 g, 0.123 mmol) dissolved in 1 ml of 50:50 ethanol/acetonitrile.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix B.
Melting Point: (Mel-temp®) 185-186˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3433 cm-1 (Amide NH stretch); 3198
cm-1 (C-H stretch, alkene); 1669 cm-1 (C=O); 1592 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (experimental): 17.335, 20.083, 24.241, 25.562, 29.100,
35.040.
4.4.3 Nicotinamide / gentisic acid 1:1 (C)
Synthesis: Colorless crystals were obtained within four days via slow evaporation
of a solution containing nicotinamide (0.015 g, 0.123 mmol) and gentisic acid
(0.019 g, 0.123 mmol) dissolved in 1 ml ethanol.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix B.
Melting Point: (Mel-temp®) 171-172˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3404 cm-1 (Amide NH stretch); 3231
cm-1 (C-H stretch, alkene); 1691 cm-1 (C=O); 1603 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (experimental): 14.860, 16.463, 25.940, 26.781, 27.677,
28.882.
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4.4.4 Pyrazinamide / gentisic acid 1:1 (D)
Synthesis: Colorless crystals were obtained within two days via slow evaporation
of a solution containing pyrazinamide (0.020 g, 0.162 mmol) and gentisic acid
(0.025 g, 0.162 mmol) dissolved in 1 ml of acetonitrile.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix B.
Melting Point: (Mel-temp®) 164-166˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3400 cm-1 (Amide NH stretch); 3231
cm-1 (C-H stretch, alkene); 1669 cm-1 (C=O); 1603 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (experimental): 19.560, 25.863, 27.580, 28.041.
4.4.5 Acetamide / gentisic acid 1:1 (E)
Synthesis: Colorless crystals were obtained within two days via slow evaporation
of a solution containing acetamide (0.059 g, 0.100 mmol) and gentisic acid
(0.015 g, 0.100 mmol) dissolved in 1 ml of acetonitrile.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix B.
Melting Point: (Mel-temp®) 141˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3371 cm-1 (Amide NH stretch); 3198
cm-1 (C-H stretch, alkene); 1658 cm-1 (C=O); 1544 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (simulated): 9.94, 16.16, 18.11, 22.85, 27.09, 30.93.
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4.5 Discussion
The hydrogen bonding capabilities of functional groups are varied and are not yet
predictable. The application of crystal engineering to competitive studies between
functional groups capable of hydrogen bonding will lead to a greater understanding of the
hierarchy of these interactions and to the ability to design a series of structures with
molecules of interest.
The preceding model compounds were used to study the hydrogen bonding
preferences of primary amides when in competitive situations with the following
functional groups: aromatic nitrogens, alcohols, and carboxylic acids. The crystal
structure of the 1:1 acetamide/ gentisic acid co-crystal (E), which contains a primary
amide, a carboxylic acid, and both meta and ortho-substituted alcohol moieties, exhibits
the expected amide-acid supramolecular heterosynthon. This projected amide-acid
supramolecular heterosynthon, as well as the alcohol-pyridine supramolecular
heterosynthon, are found in three of the remaining four structures that contain a primary
amide, a carboxylic acid, an aromatic nitrogen, and an alcohol moiety (A, B, D). The fifth
structure, that of nicotinamide and gentisic acid (C), contains an acid-pyridine
supramolecular heterosynthon, while the primary amide moiety is hydrogen bonded to
three alcohol moieties from three separate gentisic acid molecules. With four of the five
structures (80%) exhibiting the intended primary amide-carboxylic acid supramolecular
heterosynthon, there seems to be some degree of predictability regarding the hydrogen
bonding preferences of these two groups in the presence of aromatic nitrogen and alcohol
moieties.
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These results are based upon co-crystallizations with combinations of molecules
that contain a primary amide (with or without aromatic nitrogen moieties) and those that
contained a carboxylic acid (with one or more hydroxyl groups). Co-crystallization was
also attempted with molecules containing a reverse combination of functional groups,
however; attempts were unsuccessful due to a lack of suitable compounds containing
both primary amide and alcohol moieties. Further research is needed in order to support
any observations regarding the hydrogen bonding preferences in this group of selected
functionalities.
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Chapter 5
Piracetam

5.1 Description
Piracetam, (2-oxo-1-pyrrolidinyl)acetamide (fig. 18), is a nootropic drug that
works to boost intelligence by stimulating the central nervous system [54]. Three
polymorphic forms of Piracetam, refcode BISMEV, have been deposited in the CSD.
Two forms, a triclinic and a monoclinic modification, crystallize via an amide-amide
supramolecular homosynthon (fig. 19a), while the third, a monoclinic form, crystallizes
in a catemeric fashion (fig. 19b). In all three forms, the ring carbonyl is involved in
hydrogen bonding to the anti-oriented NH of the primary amide. No co-crystals, solvates
or hydrates have been reported although one study suggests that Piracetam may exhibit 6
polymorphs [55].

Figure 18. Molecular Structure of Piracetam.
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5.2 Strategy
Piracetam contains two functional groups: a primary amide and a ring carbonyl.
The design strategy for this drug was to use a co-crystal former containing a carboxylic
acid moiety in order to exploit the robust primary amide-acid supramolecular
heterosynthon, while also containing a hydrogen bond donor that could interact with the
ring carbonyl. Two such structures were synthesized with Piracetam.

Figure 19. Piracetam Polymorph Homosynthon Motifs (a) Piracetam dimer (b) Piracetam catemer.

5.3 Structures
5.3.1 Piracetam / gentisic acid 1:1 (A)
Single crystals of the 1:1 co-crystal of Piracetam and gentisic acid, A, were
obtained via slow evaporation and Figure 20 reveals that A is sustained by the primary
amide-carboxylic acid supramolecular heterosynthon. The 5-hydroxy group of gentisic
acid serves as a hydrogen bond donor to the ring carbonyl of Piracetam, resulting in a
4,4-topology network that is 2-fold interpenetrated.
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Figure 20. Piracetam / gentisic acid 1:1 pharmaceutical co-crystal.

5.3.2 Piracetam / 4-hydroxybenzoic acid 1:1 (B)
B is a 1:1 co-crystal of Piracetam and 4-hydroxybenzoic acid (fig. 21). The crystal
structure of B also reveals the presence of the amide-acid supramolecular heterosynthon,
which in turn dimerizes to form a tetrameric motif sustained by anti N-H···O hydrogen
bonding. The ring carbonyl of Piracetam and the hydroxyl group of 4-hydroxybenzoic
acid also form hydrogen bonds which link each tetramer to four others at the corners,
thereby affording a 3-fold interpenetrated network.
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Figure 21. Piracetam / 4-hydroxybenzoic acid 1:1 pharmaceutical co-crystal.

A and B were screened for the existence of polymorphs using solvent-drop
grinding, a technique that has been shown to be able to generate and control
polymorphism [56]. Mechanical grinding experiments were conducted in reaction vessels
by adding gentisic acid or p-hydroxybenzoic acid to solid Piracetam form A. Twenty
three solvents (water, acetone, methanol, ethanol, ethyl acetate, n-hexane, toluene,
acetonitrile, tetrahydrofuran, isopropyl acetate, benzyl alcohol, nitromethane, dimethyl
amine, 2-butanol, ethyl formate, acetic acid, methyl ethyl ketone, methyl tertiary butyl
ether, chlorobenzene, N-methyl pyrrolidone, 1,2-dichloroethane, dimethylsulfoxide,
dimethoxy ethane) was evaluated by adding a different solvent to each well. The samples
were ground for 20 minutes and characterized using powder X-ray diffraction. Cocrystals A or B were obtained from all conditions as a mixture with one or both of the
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starting materials, i.e. A and B do not exhibit polymorphism based on a series of solvent
mediated grinding experiments.

5.4 Synthesis and Characterization
Melting points for structures are presented in Table 3 along with melting points
for starting materials.
Table 3. Melting points of starting materials and structures, A-B.

Co-crystal
A. Piracetam / gentisic acid (1:1)
B. Piracetam / 4-hydroxybenzoic acid (1:1)

Starting Materials [ºC]
138
205
138
217

Co-crystal [ºC]
123-125
141-142

5.4.1 Piracetam / gentisic acid 1:1 (A)
Synthesis: Colorless crystals were obtained within 7 days via slow evaporation
of a solution containing Piracetam (0.016 g, 0.11 mmol) and gentisic acid (0.017g, 0.11
mmol) dissolved in 1 ml of acetonitrile.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix C.
Melting Point: (Mel-temp®) 123-125˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3360 cm-1 (Amide NH stretch); 3180
cm-1 (C-H stretch, alkene); 1651 cm-1 (C=O); 1595 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (experimental): 12.700, 14.082, 16.960, 24.794, 27.942,
32.462.
5.4.2 Piracetam / 4-hydroxybenzoic acid 1:1 (B)
Synthesis: Colorless crystals were obtained within 2 days via slow evaporation
of a solution containing Piracetam (0.010 g, 0.07 mmol) and 4-hydroxybenzoic
acid (0.010 g, 0.07 mmol) dissolved in 1 ml of acetonitrile.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix C.
Melting Point: (Mel-temp®) 141-142˚C.
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Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3408 cm-1 (Amide NH stretch); 3187
cm-1 (C-H stretch, alkene); 1658 cm-1 (C=O); 1595 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (experimental): 6.629, 13.479, 20.424.

5.5 Discussion
Piracetam contains both a primary amide and a ring ketone, two functional groups
with hydrogen bonding capabilities. According to the CSD, Piracetam has 3 known
polymorphs, all which exhibit ring carbonyl hydrogen bonding to the anti oriented NH of
the primary amide functional group.
Attempts at co-crystallization afforded two new structures; the first co-crystals
formed with this API. Both structures contain a primary amide-carboxylic acid
supramolecular heterosynthon as well as a ketone-alcohol heterosynthon. This suggests
that the amide-acid heterosynthon is more robust than amide-amide homosynthon
interactions. The ring ketone is then free to hydrogen bond with the alcohol group
present.
With both structures (100%) containing the intended primary amide-carboxylic
acid supramolecular heterosynthon, it would seem there is some degree of predictability
regarding the hydrogen bonding preferences of these two groups in the presence of ring
ketone and alcohol moieties, however; further research is needed in order to support any
observations regarding the hydrogen bonding preferences in this group of selected
functionalities.
Both co-crystals were screened for the existence of polymorphs using solvent
mediated grinding experiments with 23 different solvents. After grinding for 20 minutes
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the samples were characterized using powder X-ray diffraction. Co-crystals were
obtained from all conditions as a mixture with one or both of the starting materials,
therefore, based upon these grinding experiments, A and B do not exhibit polymorphism.
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Chapter 6
Carbamazepine
6.1 Study of an API- CBZ
The pharmaceutically active molecule Carbamazepine (CBZ) [5H-Dibenz(b,f)
azepine-5-carboxamide] (fig. 22) was of interest to us because of its limited
bioavailability [57] and four reported polymorphs [58,59]. A review of the literature and
a CSD search also reveal a dihydrate [60], an acetone solvate [58c] and two ammonium
salts [61]. It is an important drug for the treatment of epilepsy and trigeminal neuralgia
and pure CBZ crystallizes as one of four polymorphs: triclinic (form I); trigonal (form II);
monoclinic (forms III and IV). Its relevance, limited solubility and the fact that it exists
in multiple crystalline forms therefore makes CBZ an ideal candidate for a crystalengineering case study.

Figure 22. Molecular structure of Carbamazepine (CBZ).

Only five of the eight forms of CBZ isolated thus far have been reported with full
structural data (polymorphs II [58c] and III [58d], a dihydrate [60] with R factor of ~10%
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and two multiple component phases [61]) although the cell parameters of the acetone
solvate have also been reported [58c]. Analysis of crystal packing in these structures
reveals that the supramolecular primary amide homosynthon (fig. 1b) generates CBZ
dimers in all compounds and that the azepine ring adopts a boat conformation. Form II is
trigonal (fig. 23) and form III is a monoclinic phase (fig. 23) that contains cavities. The
syn- oriented N–H of the primary amide group forms the expected primary amide dimer
while the anti- oriented N–H does not engage in intermolecular interactions. A search of
the CSD revealed 440 structures containing a primary amide dimer. (organics only, N–
H…O contact 0-3.3Å). Of those 440 structures, 30% have an anti- oriented N–H that is
not involved in hydrogen bonding, most commonly due to steric hindrance.

Figure 23. Forms II and III of Carbamazepine (CBZ): Left; Trigonal Form II, Right; Monoclinic Form III.

The presence of unused hydrogen bond donor and acceptor sites is an important
issue in the context of crystal engineering. Furthermore, the different crystal packing
motifs in the polymorphs of CBZ might be attributed to molecular shape of the CBZ
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dimer and its inability to efficiently pack or utilize the inactivated anti- oriented N–H
group. Interestingly, isostructural crystal packing with the trigonal form II was identified
from the CSD. N-acetyl dibenz (b,f) azepine [62] is an analogue of CBZ in which the
amide NH2 group in CBZ is replaced with a CH3 group and therefore the supramolecular
synthon is the result of a C–H···O=C mediated homosynthon instead of a N–H···O=C
homosynthon. Form III has been reported to be the most thermodynamically stable phase
at room temperature and the one selected for use herein [63]. Interestingly, the dihydrate
structure of CBZ forms N–H···O hydrogen bonds via the anti-oriented N–H of the amide
group in addition to the two-point primary amide homosynthon and is even less soluble in
water than the pure forms [60]. It is this low solubility of CBZ in water that makes it
difficult to further extend its utility as a pharmaceutical and justifies CBZ as a candidate
for a search for more crystalline phases.
In this contribution, we present two basic strategies for such a search, both of
which might be generally applicable to APIs that contain primary amide moieties.

6.2 Strategy 1
Strategy 1 exploits the exofunctional nature of the primary amide dimer as either
a hydrogen bond donor or a hydrogen bond acceptor and thereby retains the primary
amide dimer that is present in all previously isolated forms of CBZ.
While all co-crystals and solvates generated from strategy 1 retain the primary
amide dimer motif, there are two distinct modes by which they exploit their remaining Hbonding sites: H-bond donor of CBZ to the H-bond acceptor of co-crystal former
(CBZ/benzoquinone, A (fig. 24); CBZ/4,4’-bipyridine, B (fig. 25); and both H-bond
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donor and H-bond acceptors of the CBZ to H-bond donor and H-bond acceptor sites of
the co-crystal former or solvent molecule (CBZ/cinnamic acid, C (fig. 26);
CBZ/formamide solvate, D (fig. 27).

6.3 Structures
6.3.1 CBZ / benzoquinone 2:1 (A)
The asymmetric unit of A (fig. 24) consists of one molecule of CBZ and a half
molecule of benzoquinone. The primary amide dimer [NH···O 2.900 Å] is observed
between inversion related CBZ molecules, and the benzoquinone molecules lie around
crystallographic inversion centers. The benzoquinone molecules are held by the anti N–
H···O hydrogen bond of the CBZ dimers [NH···O 3.126Å] and not only generate a void
space between the CBZ dimers but also sustain a one-dimensional ribbon due to the
presence of two acceptor sites.

Figure 24. CBZ / benzoquinone 2:1 pharmaceutical co-crystal.
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6.3.2 CBZ / 4,4’-bipyridine 2:1 (B)
The crystal structure of B reveals that the CBZ amide dimer remains intact and
the pyridine moieties act as acceptors to the anti- oriented NHs of CBZ (fig. 25). There
are 10 CSD structures that exhibit the same type of motif with a pyridine moiety [64] and
the mean bond length for the (amide)N–Ha···N (pyridine) interaction is 3.06(7) Å. B
exhibits two unique N–Ha···N bond lengths, 2.967 and 2.992 Å, as well as two distinct
primary amide dimer bond lengths of 2.908 and 2.880 Å.

Figure 25. CBZ / 4,4’-bipyridine 2:1 pharmaceutical co-crystal.

6.3.3 CBZ / cinnamic acid 1:1 (C)
In structure C, the CBZ primary amide dimer is intact and is linked with each
consecutive dimer by exterior hydrogen bonding with cinnamic acid (fig. 26). The
primary amide dimer bond length of 2.956(17) Å is very close to the mean of 2.95(5) Å
for this interaction. The mean bond length for the (amide)N–H···O(acid) interaction is
2.96(8) Å and was found to be 3.039(18) Å for C, while the mean for the (acid)O–
H…O(amide) is 2.56(6) Å and was 2.621(15) Å in this structure.

50

Figure 26. CBZ / cinnamic acid 1:1 pharmaceutical co-crystal (a.) Intact primary amide dimer; (b.) Exterior hydrogen bonding linking
the amide dimers with the cinnamic carboxylic acid groups.

6.3.4 CBZ / formamide solvate 1:1 (D)
The CBZ / formamide solvate, D (fig. 27), is a rare example of a crystal structure
that contains two chemically different amide groups that each form primary amide
homosynthons that interact only by peripheral hydrogen bonding, thereby forming an
amide-amide’ alternating tape. The pure forms of CBZ do not exhibit this tape motif,
most likely due to the sterically bulky azepine rings. In the structure D, the formamide
and CBZ dimers alternate through exterior hydrogen bonding. There are two inversion
related CBZ dimers, denoted 1 and 2, that generate a two-dimensional hydrogen bonded
pattern.

1

2

1

Figure 27. 1:1 solvate of CBZ / formamide showing the two inversion related CBZ homosynthons, 1 and 2, that generate the 2-D
hydrogen bonded structure.
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6.4 Synthesis and Characterization
Melting points for structures are presented in Table 4 along with melting points
for starting materials.
Table 4. Melting points of starting materials and structures, A-D.

Co-crystal/Solvate
A. CBZ / benzoquinone (1:1)
B. CBZ / 4,4’-bipyridine (1:1)
C. CBZ / cinnamic acid (1:1)
D. CBZ / formamide solvate (1:1)

Starting Materials [ºC]
191-192
116
191-192
111-114
191-192
133
191-192
2.5

Structure [ºC]
170
152-160
142-143
142-144

6.4.1 CBZ / benzoquinone 2:1 (A)
Synthesis: Colorless crystals were obtained within five days via slow evaporation
of a solution containing Carbamazepine (0.037 g, 0.157 mmol) and benzoquinone
(0.008 g, 0.078 mmol) dissolved in 1 ml of methanol.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix D.
Melting Point: (Mel-temp®) 170˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3420 cm-1 (Amide NH stretch); 3190
cm-1 (C-H stretch, alkene); 1672 cm-1 (C=O); 1587 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (simulated): 8.82, 15.63, 19.38, 24.59, 26.72.
6.4.2 CBZ / 4,4’-bipyridine 2:1 (B)
Synthesis: Colorless crystals were obtained within three days via slow evaporation
of a solution containing Carbamazepine (0.030 g, 0.127 mmol) and 4,4’- bipyridine
(0.027 g, 0.127 mmol) dissolved in 2 ml of 50:50 mixture of THF/CS2.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix D.
Melting Point: (Mel-temp®) 152-160˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3426 cm-1 (Amide NH stretch); 3183
cm-1 (C-H stretch, alkene); 1676 cm-1 (C=O); 1566 cm-1 (C=C).
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X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (simulated): 9.03, 12.13, 13.49, 15.18, 26.95.
6.4.3 CBZ / cinnamic acid 1:1 (C)
Synthesis: Colorless crystals were obtained within five days via slow evaporation
of a solution containing Carbamazepine (0.024 g, 0.100 mmol) and cinnamic acid
(0.015 g, 0.100 mmol) dissolved in 1 ml of ethyl acetate.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix D.
Melting Point: (Mel-temp®) 142-143˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3433 cm-1 (Amide NH stretch); 3319
cm-1 (C-H stretch, alkene); 1702 cm-1 (C=O); 1573 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (experimental): 5.78, 9.91, 16.70, 21.82, 27.24.
6.4.4 CBZ / formamide solvate 1:1 (D)
Synthesis: Colorless crystals were obtained within six days via slow evaporation
of a solution containing Carbamazepine (0.030 g, 0.127 mmol) dissolved in 1 ml
of formamide.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix D.
Melting Point: (Mel-temp®) 142-144˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3392 cm-1 (Amide NH stretch); 3178
cm-1 (C-H stretch, alkene); 1684 cm-1 (C=O); 1590 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (simulated): 8.74, 13.15, 18.74, 26.12, 26.72.
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6.5 Strategy 2
Strategy 2 breaks the CBZ primary amide dimer using co-crystal formers that are
capable of two-point interactions, thereby forming a heterosynthon between the primary
amide moiety of CBZ and a complementary functional group. In nine of following
structures, six of which are pharmaceutical co-crystals and three of which are solvates of
CBZ, the supramolecular primary amide heterosynthon is formed with a carboxylic acid
moiety. The tenth structure is an ionic compound in which the deprotonated primary
amide functional group forms a supramolecular heterosynthon with a sulfonic acid.

6.6 Structures
6.6.1 CBZ / acetylsalicylic acid 1:1 (E)
Co-crystallization of CBZ with acetylsalicylic acid (aspirin) resulted in a 1:1 cocrystal (fig. 28). The crystal structure reveals the expected amide-acid supramolecular
heterosynthon formed through O–H…O [O…O 2.564(2) Å, 167.5°] and N–H…O [N…O
2.914(3) Å, 168.4°] hydrogen bonds. Interestingly, the closest contact with the antioriented N–H of the CBZ amide moiety is the carbonyl of the acetylsalicylic acid acetyl
group with a distance of 3.187(2) Å.
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Figure 28. CBZ / acetylsalicylic acid 1:1 pharmaceutical co-crystal.

6.6.2 CBZ / 4-Aminobenzoic acid 2:1 (F)
Co-crystal F also exhibits 2:1 stoichiometry and contains both the expected
amide-acid supramolecular heterosynthon and a primary amide dimer. Two amide-acid
supramolecular heterosynthons form a tetrameric motif, which is bonded to the primary
amide dimers on each side through the amino N–H···O hydrogen bonds (fig. 29). This
tetrameric motif is found in 9 of the 69 (13%) structures in the CSD that contain amideacid supramolecular heterosynthons including CBZ solvates with acetic acid, formic acid
and butyric acid [65]. The O–H···O and N–H···O hydrogen bond lengths for the amideacid supramolecular heterosynthon are 2.540(1) Å and 2.982(2) Å, which compare to the
mean values of 2.56(6) and 2.96(8)Å, respectively.
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Figure 29. CBZ / 4-aminobenzoic acid 2:1 pharmaceutical co-crystal.

6.6.3 CBZ / 4-Aminobenzoic acid / H2O 2:1:1 (G)
Co-crystallizing the same components as F in ethanol produced a 2:1:1 co-crystal
hydrate of CBZ with 4-aminobenzoic acid and adventitious H2O. The crystal packing of
G is markedly different from that of F. It forms an eight molecule discrete unit through
O–H···O and N–H···O hydrogen bonds that contains four CBZ molecules, two 4aminobenzoic acid molecules and two water molecules (fig. 30). The insertion of the
water molecule into the amide-acid supramolecular heterosynthon to form a different
supramolecular heterosynthon is unusual but not unprecedented. Hydration or solvation
of carboxylic acids by water or alcohol molecules as open or cyclic hydrogen bond motifs
is a common phenomenon during crystallization [66] and water molecules have been
thought to facilitate interactions in organic crystals [67].
The water molecules insert between the primary amide carbonyl and the acid OH,
thereby sustaining 1-point N–H···O acid-amide supramolecular heterosynthons. The
(amide) N–H···O (acid) bond length is 2.878(2) Å vs. a mean of 2.96(8) Å. Notably, the
amide anti-oriented NH’s are not involved in hydrogen bonding.
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Figure 30. CBZ / 4-aminobenzoic acid / H2O 2:1:1 co-crystal hydrate.

6.6.4 CBZ / trimesic acid 1:1 (H)
A 1:1 supramolecular complex, H, of CBZ and trimesic acid (1,3,5benzenetricarboxylic acid) was obtained (fig. 31). The structure consists of both
carboxylic acid dimers and amide-acid supramolecular heterosynthons and forms a onedimensional pattern. One carboxylic acid group of trimesic acid forms the amide-acid
supramolecular heterosynthon with the primary amide moiety of CBZ, while carboxylic
acid groups two and three of trimesic form carboxylic acid dimers.

Figure 31. CBZ / trimesic acid 1:1 pharmaceutical co-crystal.
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6.6.5 CBZ / 5-nitroisophthalic acid 1:1 (I)
By replacing one carboxylic acid group in the trimesic acid with a size matching
nitro group, the hydrogen-bonding pattern is converted into a discrete one. Cocrystallization of CBZ with 5-nitroisophthalic acid yielded a supramolecular complex
(fig. 32) with disordered solvent molecules (not shown). Supramolecular complex I is
isostructural with H and the crystal structure of I consists of a carboxylic acid dimer and
an amide-acid supramolecular heterosynthon. The anti N–H group is activated by N–
H···O hydrogen bonding with solvent molecules. Thus all hydrogen-bonding
considerations are satisfied.

Figure 32. CBZ / 5-nitroisophthalic acid 1:1 pharmaceutical co-crystal.

6.6.6 CBZ / 2,6-pyridinedicarboxylic acid 1:1 (J)
CBZ was co-crystallized with 2,6-pyridinedicarboxylic acid from ethanol. The
expected amide-acid supramolecular heterosynthon is not seen in this structure. Rather,
the co-crystal exhibits an unusual hydrogen-bonding motif. Only one-point interactions
are present, with each CBZ molecule bonding to three distinct acid molecules. It is
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interesting to note that two carboxylic acid OH donors are hydrogen bonding with one
amide carbonyl. The two (acid)O–H···O(amide) hydrogen bonds are in the normal
distance and angle range [2.949(2) Å, 172º; 2.983(2) Å, 148.6º]. There is no disorder in
the crystal structure and the protons are located in the difference Fourier map. The two
acid OH donors are also involved in an intramolecular O–H···N [O···N 2.654, 2.681 Å]
hydrogen bond with the pyridine moiety. This unusual hydrogen bonded motif (fig. 33) is
stabilized through both intra- and intermolecular interactions thus forming an intricate
hydrogen bonded network. While it is fairly common to have (acid)OH hydrogen
bonding to a carbonyl, bifurcation [68] of a carbonyl (amide or simple ketone) to two
(acid)OH groups without a 2-point supramolecular heterosynthon present is only seen in
one structure from the CSD [69].

Figure 33. CBZ / 2,6-pyridinedicarboxylic acid 1:1 pharmaceutical co-crystal.
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6.6.7 CBZ /acetic acid solvate 1:1 (K)
X-ray quality single crystals of K (fig. 34) were grown from acetic acid. The
structure exhibits the expected amide-acid supramolecular heterosynthon, however, the
anti-oriented N–H of the amide moiety forms an inversion related N–Ha…O hydrogen
bond [2.919(2) Å] with the acetic acid carbonyl group, which generates a discrete 4component supramolecular complex rather than a tape. The length of the amide-acid O–
H…O hydrogen bond was found to be 2.553(2) Å. The orientation of CBZ azepine rings
above and below the glide related hydrogen bonded complexes form a hydrophobic
region.

Figure 34. 4-component supramolecular complex of the 1:1 acetic acid solvate of CBZ.

6.6.8 CBZ / formic acid solvate 1:1 (L)
Structure L (fig. 35) is isostructural with K. The tetrameric motif is replicated in
this solvate of CBZ with formic acid. The N-Ha…O hydrogen bond length is 2.894(2) Å,
while the amide-acid O-H···O hydrogen bond length is 2.548(2) Å. The hydrophobic
region is again present between the CBZ azepine rings of each tetramer.
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Figure 35. 4-component supramolecular complex of the 1:1 formic acid solvate of CBZ.

6.6.9 CBZ / butyric acid solvate 1:1 (M)
Structure M (fig. 36) also exhibits the tetrameric motif, however, is not
isostructural with K and L. The butyric alkyl groups fold, causing a bending of the
N-Ha…O bond [2.929(2) Å], presumably in order to facilitate the formation of the
tetrameric motif. The (acid)O-H···O(amide) hydrogen bonds are in the normal distance
range [2.589(2) Å].

Figure 36. 4-component supramolecular complex of the 1:1 butyric acid solvate of CBZ.
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6.6.10 CBZ / benzenesulfonate 1:1 (N)
Complex N (fig. 36) consists of a previously unknown heterosynthon. It exhibits
a similar tetrameric motif as seen in previous CBZ / carboxylic acid structures. The CBZ
primary amide carbonyl is protonated by the sulfonic acid making this a charge-assisted
interaction. Protonated amides can be found in the CSD with nitric [70] and phosphoric
acids [71], however; they have not been seen with sulfonic acids. Two supramolecular
heterosynthons are joined by both remaining S=O groups bonding to the anti-oriented
amide NH’s.

Figure 37. 4-component supramolecular complex of the 1:1 CBZ benzenesulfonate.

6.7 Synthesis and Characterization
Melting points for structures are presented in Tables 5-6 along with melting points
for starting materials.
Table 5. Melting points of starting materials and structures, E-I.

Co-crystal
A. CBZ / acetylsalicylic acid (1:1)
B. CBZ / 4-aminobenzoic acid (1:1)
C. CBZ / 4-aminobenzoic acid hydrate (2:1:1)
D. CBZ / trimesic acid (1:1)
E. CBZ / 5-nitroisophthalic acid (1:1)

Starting Materials [ºC]
191-192
135
191-192
189
191-192
189
191-192
380
191-192
260-261
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Co-crystal [ºC]
125-126
185-187
143
278 (dec)
190 (dec)

Table 6. Melting points of starting materials and structures, J-N.

Co-crystal/Salt
A. CBZ / 2,6-pyridinedicarboxylic acid (1:1)
B. CBZ / acetic acid solvate (1:1)
C. CBZ / formic acid solvate (1:1)
D. CBZ / butyric acid solvate (1:1)
E. CBZ benzenesulfonate (1:1)

Starting Materials [ºC]
191-192
245-250
191-192
16.6
191-192
8.4
191-192
-7.9
191-192
43-44

Structure [ºC]
214-216
187
187
120
118-122

6.7.1 CBZ / acetylsalicylic acid 1:1 (E)
Synthesis: Colorless crystals were obtained within one day via slow evaporation
of a solution containing Carbamazepine (0.024 g, 0.100 mmol) and acetylsalicylic
acid (0.018 g, 0.100 mmol) dissolved in 1 ml of ethyl acetate.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix E.
Melting Point: (Mel-temp®) 125-126˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3422 cm-1 (Amide NH stretch); 3216
cm-1 (C-H stretch, alkene); 1691 cm-1 (C=O); 1606 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (experimental): 12.707, 13.442, 17.681, 19.503, 24.840,
25.861, 29.420, 31.980, 33.080.
6.7.2 CBZ / 4-aminobenzoic acid 2:1 (F)
Synthesis: Yellow crystals were obtained within three days via slow evaporation
of a solution containing Carbamazepine (0.014 g, 0.059 mmol) and 4-aminobenzoic acid
(0.016 g, 0.118 mmol) dissolved in 1 ml of methanol.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix E.
Melting Point: (Mel-temp®) 185-187˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3460 cm-1 (Amide NH stretch); 3162
cm-1 (C-H stretch, alkene); 1673 cm-1 (C=O); 1603 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (experimental): 9.540, 14.701, 15.963, 17.470, 19.225,
21.640, 26.463.
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6.7.3 CBZ / 4-aminobenzoic acid / H2O 2:1:1 (G)
Synthesis: Yellow crystals were obtained within three days via slow evaporation of a
solution containing CBZ (0.015 g, 0.063 mmol) and 4-aminobenzoic acid
(0.0087 g, 0.063 mmol) dissolved in 1 ml of ethanol.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix E.
Melting Point: (Mel-temp®) 143˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3480 cm-1 (Amide NH stretch); 3217
cm-1 (C-H stretch, alkene); 1658 cm-1 (C=O); 1547 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (experimental): 8.413, 14.387, 16.645, 17.920, 22.791,
24.820, 26.392, 31.430.
6.7.4 CBZ / trimesic acid 1:1 (H)
Synthesis: Colorless crystals were obtained within seven days via slow evaporation of a
solution containing Carbamazepine (0.036 g, 0.152 mmol) and trimesic acid (0.032 g,
0.152 mmol) dissolved in 4 ml of a 50:50 mixture of methanol and dichloromethane.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix E.
Melting Point: (Mel-temp®) 278˚C (dec).
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3486 cm-1 (Amide NH stretch); 3206
cm-1 (C-H stretch, alkene); 1688 cm-1 (C=O); 1602 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA. XPD analysis (experimental): 10.732, 12.575, 24.045, 27.235, 29.369.
6.7.5 CBZ / 5-nitroisophthalic acid 1:1 (I)
Synthesis: Yellow crystals were obtained within four days via slow evaporation of a
solution containing Carbamazepine (0.015 g, 0.123 mmol) and 5-nitroisophthalic acid
(0.017 g, 0.123 mmol) dissolved in 1 ml of methanol.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix E.
Melting Point: (Mel-temp®) 190˚C (dec).
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Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3470 cm-1 (Amide NH stretch); 3178
cm-1 (C-H stretch, alkene); 1688 cm-1 (C=O); 1602 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (experimental): 10.283, 15.607, 17.791, 21.685, 31.740,
32.729.
6.7.6 CBZ / 2,6-pyridinedicarboxylic acid 1:1 (J)
Synthesis: Colorless crystals were obtained within one half hour via slow evaporation of
a solution containing Carbamazepine (0.034 g, 0.144 mmol) and (0.024 g, 0.144 mmol)
dissolved in 1 ml of ethanol.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix F.
Melting Point: (Mel-temp®) 214-216˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3439 cm-1 (Amide NH stretch); 3186
cm-1 (C-H stretch, alkene); 1734 cm-1 (C=O); 1649 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (simulated): 7.85, 13.09, 14.58, 17.98, 25.94, 27.41, 29.06.
6.7.7 CBZ / acetic acid solvate 1:1 (K)
Synthesis: Colorless crystals were obtained within five days via slow evaporation of a
solution containing Carbamazepine (0.024 g, 0.100 mmol) dissolved in 1 ml of acetic
acid.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix F.
Melting Point: (Mel-temp®) 187˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3462 cm-1 (Amide NH stretch); 3315
cm-1 (C-H stretch, alkene); 1699 cm-1 (C=O); 1629 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (simulated): 9.62, 11.25, 14.82, 19.49, 20.78, 25.22.
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6.7.8 CBZ / formic acid solvate 1:1 (L)
Synthesis: Colorless crystals were obtained within five days via slow evaporation of a
solution containing Carbamazepine (0.024 g, 0.100 mmol) dissolved in 1 ml of formic
acid.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix F.
Melting Point: (Mel-temp®) 187˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3439 cm-1 (Amide NH stretch); 3318
cm-1 (C-H stretch, alkene); 1692 cm-1 (C=O); 1633 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (simulated): 9.90, 12.00, 15.63, 18.23, 20.66, 26.02, 27.98.
6.7.9 CBZ / butyric acid solvate 1:1 (M)
Synthesis: Colorless crystals were obtained within six days via slow evaporation of a
solution containing Carbamazepine (0.024 g, 0.100 mmol) dissolved in 1 ml of butyric
acid.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix F.
Melting Point: (Mel-temp®) 120˚C.
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3486 cm-1 (Amide NH stretch); 3307
cm-1 (C-H stretch, alkene); 1684 cm-1 (C=O); 1540 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (simulated): 9.09, 11.95, 16.63, 18.53, 24.05, 26.83.
6.7.10 CBZ /benzenesulfonate 1:1 (N)
Synthesis: Yellow crystals were obtained within four days via slow evaporation of a
solution containing Carbamazepine (0.024 g, 0.100 mmol) and benzenesulfonic acid
(0.016 g, 0.100 mmol) dissolved in 1 ml of ethyl acetate.
Crystal data: (Bruker SMART-APEX CCD Diffractometer) Appendix F.
Melting Point: (Mel-temp®) 118-122˚C.
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Infrared Spectroscopy: (Nicolet Avatar 320 FTIR) 3462 cm-1 (Amide NH stretch); 3171
cm-1 (C-H stretch, alkene); 1649 cm-1 (C=O); 1583 cm-1 (C=C).
X-ray Powder Diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562),
30kV, 15mA). XPD analysis (experimental): 10.530, 13.961, 15.225, 16.890, 19.293,
22.460, 25.544, 27.861.
6.8 Discussion
The focus of this study is the understanding of the primary amide functional
group and its hydrogen bonding capabilities; as well as the synthesis of multiplecomponent crystalline phases in order to develop a method for the design of
pharmaceutical co-crystals using API’s that contain a primary amide functional group.
The pharmaceutically active molecule carbamazepine (CBZ) is a well-known
drug used in the treatment of epilepsy and trigeminal neuralgia and was chosen as a
candidate for this crystal engineering case study due to its limited bioavailability, limited
solubility in water, and the existence of multiple crystalline forms.
The key supramolecular synthon in CBZ is the primary amide moiety, which has
already been shown to be a reliable supramolecular synthon in the formation of multiplecomponent crystalline architectures [51,72].
Two basic strategies were employed to exploit the hydrogen bonding capabilities
of the primary amide moiety found in CBZ. Strategy 1 takes advantage of the
exofunctional nature of the primary amide dimer as either a hydrogen bond donor or a
hydrogen bond acceptor and in so doing retains the primary amide dimer that is present in
all previously isolated forms of CBZ. Strategy 2 breaks the CBZ primary amide dimer
using co-crystal formers that are capable of two-point interactions, thereby forming a
supramolecular heterosynthon between the primary amide moiety of CBZ and the
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complementary functional group of a co-crystal former or solvate molecule. The results
of these two strategies are 9 pharmaceutical co-crystals, 4 solvates, and 1 salt of this wellstudied API.
Of the 10 CBZ structures containing a carboxylic acid co-crystal former, 9 (90%)
exhibit the expected primary amide-carboxylic acid supramolecular heterosynthon. It
would seem there is a high degree of predictability regarding the hydrogen bonding
preferences of these two groups. Further research is needed in order to support any
observations regarding the hydrogen bonding preferences between these selected
functionalities.
In summary, we have shown that it is possible to exploit an API containing a
primary amide moiety for the formation of a diverse range of multiple-component
crystalline phases by utilizing appropriate co-crystal formers. This paradigm of modular
design means that even without covalent modification a wide range of new compositions
of matter are readily accessible utilizing existing APIs.
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Chapter 7

Conclusions

Crystal engineering can be defined as the application of supramolecular chemistry
to the solid state. Although it was initially introduced in the context of stereochemical
control of photochemical reactions [2], it has most recently evolved into a form of
supramolecular synthesis for new solid phases using directional and reproducible
molecular recognition events known as supramolecular synthons. The work of this thesis
is based upon the exploitation of these supramolecular synthons in order to rationally
design multiple component crystalline phases or co-crystals with predictable
stoichiometry and architecture.
The potential impacts of co-crystals appear to be quite broad. They have been
shown to be applicable to many types of studies including new classes of NLO materials
[20], organic solid-state synthesis [21], reformulation of APIs [4,11,19], design of hostguest systems [17] and delineation of the hierarchy of hydrogen bonded supramolecular
synthons in competitive situations [29].
Crystal structures are unpredictable by nature, however, the interactions that lead
to crystal formation are becoming much more predictable. By means of model compound
studies, the delineation of the hierarchy of hydrogen bonding between complementary
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functional groups or supramolecular heterosynthons can be accomplished. Competitive
co-crystallization studies along with data extracted from the Cambridge Structural
Database (CSD) can be utilized in understanding the reliability of supramolecular
heterosynthons without the need for endless co-crystallization experiments which involve
numerous variables including, but not limited to temperature, solvent selection,
concentration, and crystallinity and packing efficiency of the starting materials.
Co-crystals are typically synthesized by slow evaporation from solution that
contains stoichiometric amounts of the parent compounds; however, sublimation, growth
from the melt, slurry conversion and grinding are also suitable methodologies.
Techniques used for the characterization of co-crystals include single crystal x-ray
diffraction, infrared spectroscopy, differential scanning calorimetry, thermogravimetric
analysis, melting point apparatus, and powder x-ray diffraction.
In effect, this ability to understand supramolecular heterosynthons, along with
knowledge of optimal crystallization and characterization techniques, can allow crystal
engineers to reasonably design co-crystals with a high rate of success. Using a rational
design plan, supramolecular synthesis of 17 new structures containing both a primary
amide and a carboxylic acid functional group was achieved, wherein 15 of the 17
structures (88%) exhibit the amide-acid supramolecular heterosynthon. In this
contribution, it has been demonstrated that, whereas functional groups can exhibit varied
hydrogen bonding motifs, there is some degree of predictability in the formation of
supramolecular heterosynthons.
Although co-crystals have been recognized for decades, they have only recently
been of interest in the pharmaceutical industry due to the fact that they are amenable to
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control and design (crystal engineering) in a manner not possible with other forms of
API's such as salts, solvates, and polymorphs. Also, as APIs can exhibit problems ranging
from poor solubility, polymorphism and inadequate dissolution properties to lack of
crystallinity and instability, pharmaceutical co-crystals offer an opportunity to increase
the number of forms of an API and to address some these problems.
It has been suggested that pharmaceutical co-crystals could play a significant part
in the future of API formulation since in principle they will outnumber pharmaceutical
salts, polymorphs and solvates combined.
The relevance of crystal engineering in API formulation includes the ability to
fine-tune physical properties without changing the molecular structure of the API,
identification of novel forms of polymorphic API's, and the opportunity to generate a
broader range of intellectual property than with present methods.
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Appendix A: Crystallographic Data for Polymorphic Structures A-D

A

B

C

D

c11h16o2

c11h16o2

c9h8o4

c9h8o4

Molecular Weight

180.24

180.24

180.15

180.15

Crystal System

Triclinic

Trigonal

Monoclinic

Monoclinic

P-1

R-3

P2(1)/c

P2(1)/c

100(2)

100(2)

100(2)

100(2)

a (Å)

6.3179(11)

24.2612(11)

11.233(3)

12.095(7)

b (Å)

14.364(3)

24.2612(11)

6.544(1)

6.491(4)

c (Å)

17.960(3)

9.3049(8)

11.231(3)

11.232(6)

α (deg)

74.636(3)

90

90

90

β (deg)

80.608(4)

90

95.89(2)

111.509(9)

86.767(3)

120

90

90

1550.5(5)

4743.1(5)

821.218

827.1(8)

1.158

1.136

1.456

1.447

H2O/EtOH

ACN

135

128-130

Formula

Space Group
Temperature (K)

γ (deg)
3

Volume (Å )
Calc Density (mg/cm-3)
Solvent
Melting Point (ºC)

61

65
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Appendix B: Crystallographic Data for Model Compound Structures A-E

A

B

C

D

E

c13h12n2o4

c13h12n2o4

c13h12n2o5

c12h11n3o5

c9h11no5

260.25

260.25

276.25

277.24

213.19

Monoclinic

Monoclinic

Orthorhombic

Monoclinic

Monoclinic

Space Group

P2(1)/c

C2/c

P2(1)2(1)2(1)

P2(1)/n

P2(1)/c

Temperature (K)

100(2)

100(2)

100(2)

100(2)

298(2)

a (Å)

7.3699(13)

30.877(6)

6.956(6)

6.5355(10)

11.019(3)

b (Å)

7.1977(13)

7.2172(13)

12.700(8)

17.696(3)

5.1501(14)

c (Å)

22.688(4)

11.173(2)

14.075(10)

10.2538(16)

17.877(5)

α (deg)

90

90

90

90

90

β (deg)

91.809(3)

107.521(4)

90

94.645(3)

95.832(5)

γ (deg)

90

90

90

90

90

1202.9(4)

2374.4(7)

1243.5(16)

1182.0(3)

1009.3(5)

Calc Density (mg/cm-3)

1.437

1.456

1.476

1.558

1.403

Solvent

ACN

EtOH/ACN

EtOH

ACN

ACN

123-125

185-186

171-172

164-166

141

Formula
Molecular Weight
Crystal System

Volume (Å3)

Melting Point (ºC)
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Appendix C: Crystallographic Data for Piracetam Structures A-B

A

B

c13h16n2o5

c13h16n2o6

280.28

296.28

Monoclinic

Monoclinic

Space Group

P2(1)/n

C2/c

Temperature (K)

100(2)

100(2)

a (Å)

14.780(3)

27.896(3)

b (Å)

5.5029(12)

5.1762(5)

c (Å)

17.068(4)

19.7879(18)

α (deg)

90

90

β (deg)

109.557(4)

101.090(2)

90

90

1308.0(5)

2803.9(4)

Calc Density (mg/cm-3)

1.423

1.404

Solvent

ACN

ACN

Melting Point (ºC)

124

141-142

Formula
Molecular Weight
Crystal System

γ (deg)
3

Volume (Å )

82

Appendix D: Crystallographic Data for Carbamazepine Structures A-D

A

B

C

D

c21h16n2o3

c40h32n6o2

c24h20n2o3

c16h15n3o2

344.36

628.72

384.42

281.31

Monoclinic

Triclinic

Monoclinic

Triclinic

Space Group

P2(1)/c

P-1

P2(1)/c

P-1

Temperature (K)

100(2)

100(2)

100(2)

100(2)

a (Å)

10.3335(18)

7.1053(8)

15.2187(15)

5.1077(11)

b (Å)

27.611(5)

11.801(1)

5.4243(5)

16.057(3)

c (Å)

4.9960(9)

19.648(2)

23.435(2)

17.752(4)

α (deg)

90

93.657(2)

90

73.711(3)

β (deg)

102.275(3)

92.800(2)

95.346(2)

89.350(3)

90

91.061(2)

90

88.636(3)

1392.9(4)

1641.8(3)

1926.1(3)

1397.1(5)

Calc Density (mg/cm-3)

1.232

1.272

1.326

1.337

Solvent

MeOH

THF/CS2

EtoAC

formamide

170

152-160

142-143

142-144

Formula
Molecular Weight
Crystal System

γ (deg)
3

Volume (Å )

Melting Point (ºC)

83

Appendix E: Crystallographic Data for Carbamazepine Structures E-I

E

F

G

H

I

c24h20n2o5

c30h24n4o9

c37h33n5o5

c24h18n2o7

c47h40n6o16

Molecular Weight

416.42

609.67

627.68

446.26

944.85

Crystal System

Triclinic

Monoclinic

Monoclinic

Monoclinic

Monoclinic

P-1

C2/c

P2(1)/n

C2/c

C2/c

100(2)

100(2)

100(2)

100(2)

200(2)

a (Å)

9.0317(18)

37.013(3)

13.760(1)

32.5312(50)

34.355(8)

b (Å)

11.364(2)

12.1319(9)

17.457 (1)

5.2697(8)

5.3795(13)

c (Å)

11.424(2)

13.599(1)

14.624 (1)

24.1594(37)

23.654(6)

α (deg)

60.350(4)

90

90

90

90

β (deg)

85.599(4)

99.173(1)

115.876(1)

98.191(3)

93.952(6)

84.724(4)

90

90

90

90

1014.0(3)

6028.4(8)

3160.8(4)

4099.39(37)

4361.2(18)

Calc Density (mg/cm-3)

1.364

1.343

1.319

1.439

1.439

Solvent

EtoAC

EtOH

MeOH

MeOH/CH2Cl2

MeOH

125-126

185-187

143

278(dec)

190(dec)

Formula

Space Group
Temperature (K)

γ (deg)
3

Volume (Å )

Melting Point (ºC)
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Appendix F: Crystallographic Data for Carbamazepine Structures J-N

J

K

L

M

N

c22h17n4o5

c17h16n2o2

c16h14n2o3

c19h20n2o3

c21h18n2o4s

403.39

296.32

282.29

324.37

394.43

Crystal System

Orthorhombic

Monoclinic

Monoclinic

Triclinic

Monoclinic

Space Group

P2(1)2(1)2(1)

P2(1)/c

P2(1)/c

P-1

P2(1)/n

153(2)

100(2)

100(2)

100(2)

100(2)

a (Å)

7.208(1)

5.1206(4)

5.2031(9)

9.1567(12)

13.8557(16)

b (Å)

14.644(3)

15.7136(13)

14.741(2)

10.1745(13)

8.0697(10)

c (Å)

17.577(4)

18.4986(15)

17.882(3)

10.5116(14)

16.847(2)

α (deg)

90

90

90

72.850(3)

90

β (deg)

90

96.5460(10)

98.132(3)

70.288(2)

94.815(2)

90

90

90

67.269(2)

90

1855.4(6)

1478.8(2)

1357.7(4)

834.91(19)

1877.0(4)

Calc Density (mg/cm-3)

1.444

1.331

1.381

1.290

1.396

Solvent

EtOH

acetic acid

formic acid

butyric acid

EtoAC

214-216

187

187

63-64

118-122

Formula
Molecular Weight

Temperature (K)

γ (deg)
3

Volume (Å )

Melting Point (ºC)
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